The effects of a selective inhibitor of tryptophan 2,3-dioxygenase and a combined inhibitor of tryptophan 2,3-dioxygenase and 5-HT reuptake on serotonergic function in the rat.
Wellcome Research Beckenham, United Kingdom.
M
M
Salter
R
R
Hazelwood
C I
CI
Pogson
R
R
Iyer
D J
DJ
Madge
H T
HT
Jones
B R
BR
Cooper
R F
RF
Cox
C M
CM
Wang
R P
RP
Wiard
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005473:Fluoxetine / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology*; D007700:Kinetics; D010293:Pargyline / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology*; D011903:Raphe Nuclei / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D012701:Serotonin / Q000378:metabolism*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D014364:Tryptophan / Q000378:metabolism* / Q000494:pharmacology; D014366:Tryptophan Oxygenase / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D005473:Fluoxetine; D007211:Indoles; D010293:Pargyline; D011725:Pyridines; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D014364:Tryptophan; D014366:Tryptophan Oxygenase; C093792:TDO inhibitor LM10; C104253:709W92